Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-07-10

FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approves a supplemental application for NAGLAZYME (galsulfase) by BioMarin Pharmaceutical Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NAGLAZYME (GALSULFASE)

Snippet

SUPPL AP for NAGLAZYME (GALSULFASE)